NO20053032L - Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon. - Google Patents

Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon.

Info

Publication number
NO20053032L
NO20053032L NO20053032A NO20053032A NO20053032L NO 20053032 L NO20053032 L NO 20053032L NO 20053032 A NO20053032 A NO 20053032A NO 20053032 A NO20053032 A NO 20053032A NO 20053032 L NO20053032 L NO 20053032L
Authority
NO
Norway
Prior art keywords
regulation
disturbance
treatment
production
compounds
Prior art date
Application number
NO20053032A
Other languages
English (en)
Inventor
Jose Esteve-Soler
Inigo Saenz De Tejada-Gorman
Javier Angulo-Frutos
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO20053032L publication Critical patent/NO20053032L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelsen av 2, 5-dihydroxybenzensulfonforbindelser for fremstilling av medikamenter for regulering av nitrogenoksid (NO) syntese og/eller regulering av EDHF (Endothelium-Derived-Hyperpolarizing-Factor) i endotelium hos diabetiske pasienter, hvorved medikamentet blir administrert i en daglig dose av 2, 5dihydroxybenzensulfonforbindelsene med formel (I) på < 500 mg.
NO20053032A 2002-11-29 2005-06-20 Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon. NO20053032L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202755A ES2208124B1 (es) 2002-11-29 2002-11-29 Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
PCT/EP2003/013469 WO2004050075A1 (en) 2002-11-29 2003-11-29 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function

Publications (1)

Publication Number Publication Date
NO20053032L true NO20053032L (no) 2005-06-20

Family

ID=32405966

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053032A NO20053032L (no) 2002-11-29 2005-06-20 Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon.

Country Status (13)

Country Link
US (1) US20060135611A1 (no)
EP (1) EP1596850A1 (no)
JP (1) JP2006509778A (no)
CN (1) CN1744891A (no)
AR (1) AR042152A1 (no)
AU (1) AU2003289914A1 (no)
BR (1) BR0316134A (no)
CA (1) CA2507750A1 (no)
ES (1) ES2208124B1 (no)
MX (1) MXPA05005719A (no)
NO (1) NO20053032L (no)
RU (1) RU2005120634A (no)
WO (1) WO2004050075A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080481A1 (ja) * 2005-01-31 2006-08-03 Kyorin Pharmaceutical Co., Ltd. マルチプルユニット型経口徐放性製剤及びその製造方法
FR2902096B1 (fr) * 2006-06-13 2011-03-18 Rhodia Recherches & Tech Procede de preparation de dihydroxybenzenedisulfonates metalliques
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
US20080182513A1 (en) * 2007-01-29 2008-07-31 Hassan Amer A High Frequency Communications
CN102038671B (zh) * 2010-06-29 2012-07-04 辽宁思百得医药科技有限公司 包含左卡尼汀和羟苯磺酸盐的药物组合物
CN114601816B (zh) * 2021-10-09 2022-09-02 北京惠之衡生物科技有限公司 一种羟苯磺酸钙胶囊组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608045B1 (fr) * 1986-12-12 1990-03-02 Chauvin Laboratoires Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
FR2656525A1 (fr) * 1989-12-29 1991-07-05 Delalande Sa Formes d'administration de medicament a liberation controlee et leur procede de fabrication.
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
AU715600B2 (en) * 1996-04-03 2000-02-03 Laboratorios Del Dr. Esteve, S.A. Use of 2,5-dihydroxybenzenesulfonic derivatives for the manufacture of medicaments intended for the normalization of the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, as well as vascular disorders of endothelial origin
DE10016356B4 (de) * 2000-04-03 2007-06-21 Beisel, Günther Mittel mit verbesserter Retardwirkung und Verfahren zu dessen Herstellung

Also Published As

Publication number Publication date
ES2208124B1 (es) 2005-10-01
WO2004050075A1 (en) 2004-06-17
AU2003289914A1 (en) 2004-06-23
JP2006509778A (ja) 2006-03-23
US20060135611A1 (en) 2006-06-22
ES2208124A1 (es) 2004-06-01
MXPA05005719A (es) 2005-08-16
EP1596850A1 (en) 2005-11-23
AR042152A1 (es) 2005-06-08
CA2507750A1 (en) 2004-06-17
CN1744891A (zh) 2006-03-08
BR0316134A (pt) 2005-10-11
RU2005120634A (ru) 2006-03-27

Similar Documents

Publication Publication Date Title
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer&#39;s disease
EA200400881A1 (ru) Азаарилпиперазины
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
NO20005912L (no) Sulfonylsyre- eller sulfonylamino-N-(heteroaralkyl)- azaheterocyklylamidforbindelser
CA2274686A1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
RU2004126447A (ru) Лечение ревматоидного артрита
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
BR0316134A (pt) Uso dos compostos dihidroxibenzenosulfónicos para a fabricação de um medicamento destinado a regulação da sìntese do óxido nìtrico (no) e/ou regulação do fhde
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
LT2006026A (lt) 2,5-dihidroksibenzensulfoninių junginių panaudojimas sutrikimų, paremtų no produkcijos susilpnėjimu, gydymui ir/arba edhf funkcijos reguliavimo pablogėjimui
DE60035177D1 (de) Arzneimittel für trockene haut
RU2005140516A (ru) Применение ингибитора тирозинкиназы для лечения диабета
Galatsis SECTION VII. TRENDS AND PERSPECTIVES
LT2006025A (lt) 2,5-dihidroksibenzensulfoninių junginių panaudojimas sutrikimų, paremtų no produkcijos susilpnėjimu, gydymui ir/arba edhf funkcijos reguliavimui
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
WO2005011591A2 (en) Method for the treatment of sleep disorders
HUP0402118A2 (hu) Propionil-L-karnitin vagy gyógyászatilag elfogadható sója, alkalmazása peyronie-betegség kezelésére szánt gyógyászati készítmény előállítására
CY1115006T1 (el) Παρατεταμενη απελευθερωση αντιμολυσματικων φαρμακων
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen
UY25339A1 (es) Procedimiento para la preparacion de medicamentos conteniendo compuestos utilizados en el tratamiento del sindrome de la apnea del sueño.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application